229 related articles for article (PubMed ID: 29473485)
1. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
Pujari S; Gaikwad S; Bele V; Joshi K; Dabhade D
J Int Assoc Provid AIDS Care; 2018; 17():2325958218759211. PubMed ID: 29473485
[TBL] [Abstract][Full Text] [Related]
2. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
[TBL] [Abstract][Full Text] [Related]
4. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
5. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
[TBL] [Abstract][Full Text] [Related]
7. High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.
Vidal JE; Song AT; Matos ML; Bartmann D; Anjos GD; Miranda ÉJ; Freitas ÂC; Dalben Mde F; Santana C; Segurado AC; Barreto CC; Hernández AV
Braz J Infect Dis; 2013; 17(1):41-7. PubMed ID: 23294644
[TBL] [Abstract][Full Text] [Related]
8. The maraviroc expanded access program - safety and efficacy data from an open-label study.
Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
10. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
[TBL] [Abstract][Full Text] [Related]
11. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Willig JH; Wilkins SA; Tamhane A; Nevin CR; Mugavero MJ; Raper JL; Napolitano LA; Saag MS
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):105-11. PubMed ID: 22881368
[TBL] [Abstract][Full Text] [Related]
13. Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.
Biscione FM; Westin MR; Ribeiro KM; Estevam DL; Cardoso SW; Tenore SB; Neto LF; Alencastro PR; Suffert TA; de Moraes MJ; Barbosa AN; Morejón KM; de Arruda ÉA; Silveira JM; Neto JL; Greco DB; Tupinambás U
J Int Assoc Provid AIDS Care; 2014; 13(1):63-8. PubMed ID: 24134962
[TBL] [Abstract][Full Text] [Related]
14. Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil.
Santos AMRD; Martins AP; Juliato D; de Miranda ÉJFP; Lopes GISL; Brígido LFM; Vidal JE
Int J STD AIDS; 2020 Sep; 31(10):967-975. PubMed ID: 32698729
[TBL] [Abstract][Full Text] [Related]
15. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
16. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
17. Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
Potard V; Reynes J; Ferry T; Aubin C; Finkielsztejn L; Yazdanpanah Y; Costagliola D;
PLoS One; 2015; 10(12):e0144746. PubMed ID: 26714012
[TBL] [Abstract][Full Text] [Related]
18. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Akanmu AS; Adeyemo T; Lesi F; Bello FO; Okwuegbuna K; Oloko K; Awolola A; Ogunsola FT; Okonkwo P; Kanki PJ
Curr HIV Res; 2015; 13(3):176-83. PubMed ID: 25986368
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
[TBL] [Abstract][Full Text] [Related]
20. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]